{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:15:03Z","timestamp":1785366903722,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11095-026-04124-1","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:37:15Z","timestamp":1779914235000},"page":"2025-2039","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-Dose Sunitinib Accelerates Triple-Negative Breast Cancer Metastasis by Modulating an Immunosuppressive Microenvironment: A Preclinical 4T1 Model Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Chen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-8080","authenticated-orcid":false,"given":"Tianyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"21","key":"4124_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182\u20136. https:\/\/doi.org\/10.1056\/NEJM197111182852108.","journal-title":"N Engl J Med"},{"issue":"1","key":"4124_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00838-y","volume":"20","author":"MJ Ansari","year":"2022","unstructured":"Ansari MJ, Bokov D, Markov A, Jalil AT, Shalaby MN, Suksatan W, et al. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal. 2022;20(1):49. https:\/\/doi.org\/10.1186\/s12964-022-00838-y.","journal-title":"Cell Commun Signal"},{"issue":"9","key":"4124_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012;30(9):921\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.35.7376.","journal-title":"J Clin Oncol"},{"issue":"2\u20133","key":"4124_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/BD-160218","volume":"36","author":"A Elgebaly","year":"2016","unstructured":"Elgebaly A, Menshawy A, El Ashal G, Osama O, Ghanem E, Omar A, et al. Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: a systematic review and meta-analysis. Breast Dis. 2016;36(2\u20133):91\u2013101. https:\/\/doi.org\/10.3233\/BD-160218.","journal-title":"Breast Dis"},{"issue":"3","key":"4124_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232\u20139. https:\/\/doi.org\/10.1016\/j.ccr.2009.01.021.","journal-title":"Cancer Cell"},{"issue":"1","key":"4124_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01346-y","volume":"22","author":"D Wang","year":"2020","unstructured":"Wang D, Xiao F, Feng Z, Li M, Kong L, Huang L, et al. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence. Breast Cancer Res. 2020;22(1):103. https:\/\/doi.org\/10.1186\/s13058-020-01346-y.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"4124_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/path.4052","volume":"227","author":"AS Chung","year":"2012","unstructured":"Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol. 2012;227(4):404\u201316. https:\/\/doi.org\/10.1002\/path.4052.","journal-title":"J Pathol"},{"issue":"43","key":"4124_CR8","doi-asserted-by":"publisher","first-page":"17069","DOI":"10.1073\/pnas.0708148104","volume":"104","author":"JM Ebos","year":"2007","unstructured":"Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007;104(43):17069\u201374. https:\/\/doi.org\/10.1073\/pnas.0708148104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"4124_CR9","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","volume":"27","author":"AX Zhu","year":"2009","unstructured":"Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of Sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27(18):3027\u201335. https:\/\/doi.org\/10.1200\/JCO.2008.20.9908.","journal-title":"J Clin Oncol"},{"issue":"22","key":"4124_CR10","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1200\/JCO.2007.15.5416","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of Sunitinib in patients with Bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26(22):3743\u20138. https:\/\/doi.org\/10.1200\/JCO.2007.15.5416.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4124_CR11","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023;186(8):1564\u201379. https:\/\/doi.org\/10.1016\/j.cell.2023.03.003.","journal-title":"Cell"},{"issue":"11","key":"4124_CR12","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1172\/JCI81187","volume":"125","author":"S Kurtulus","year":"2015","unstructured":"Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125(11):4053\u201362. https:\/\/doi.org\/10.1172\/JCI81187.","journal-title":"J Clin Invest"},{"issue":"1","key":"4124_CR13","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327\u201337.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4124_CR14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/aps.2016.55","volume":"37","author":"JY Li","year":"2016","unstructured":"Li JY, Ren YP, Yuan Y, Ji SM, Zhou SP, Wang LJ, et al. Preclinical PK\/PD model for combined administration of Erlotinib and Sunitinib in the treatment of A549 human NSCLC xenograft mice. Acta Pharmacol Sin. 2016;37(7):930\u201340. https:\/\/doi.org\/10.1038\/aps.2016.55.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"4124_CR15","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","volume":"69","author":"H Xin","year":"2009","unstructured":"Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009;69(6):2506\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4323.","journal-title":"Cancer Res"},{"issue":"47","key":"4124_CR16","doi-asserted-by":"publisher","first-page":"18513","DOI":"10.1073\/pnas.0807967105","volume":"105","author":"Y Xue","year":"2008","unstructured":"Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci U S A. 2008;105(47):18513\u20138. https:\/\/doi.org\/10.1073\/pnas.0807967105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"4124_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/01.coc.0000135344.25259.99","volume":"27","author":"J Lokich","year":"2004","unstructured":"Lokich J. Tumor response and survival end points in clinical trials: a clinician\u2019s perspective. Am J Clin Oncol. 2004;27(5):494\u20136. https:\/\/doi.org\/10.1097\/01.coc.0000135344.25259.99.","journal-title":"Am J Clin Oncol"},{"issue":"6024","key":"4124_CR18","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559\u201364. https:\/\/doi.org\/10.1126\/science.1203543.","journal-title":"Science"},{"key":"4124_CR19","doi-asserted-by":"publisher","unstructured":"DuPre SA, Hunter KW Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol. 2007;82(1):12\u201324. https:\/\/doi.org\/10.1016\/j.yexmp.2006.06.007.","DOI":"10.1016\/j.yexmp.2006.06.007"},{"key":"4124_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.928328","volume":"13","author":"N Ye","year":"2022","unstructured":"Ye N, Cai J, Dong Y, Chen H, Bo Z, Zhao X, et al. A multi-omic approach reveals utility of CD45 expression in prognosis and novel target discovery. Front Genet. 2022;13:928328. https:\/\/doi.org\/10.3389\/fgene.2022.928328.","journal-title":"Front Genet"},{"issue":"6","key":"4124_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s1074-7613(00)80574-9","volume":"8","author":"LL Lanier","year":"1998","unstructured":"Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94\/NKG2C NK cell receptors. Immunity. 1998;8(6):693\u2013701. https:\/\/doi.org\/10.1016\/s1074-7613(00)80574-9.","journal-title":"Immunity"},{"issue":"16","key":"4124_CR22","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1158\/0008-5472.CAN-11-1687","volume":"71","author":"A Gonzalez-Martin","year":"2011","unstructured":"Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res. 2011;71(16):5455\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1687.","journal-title":"Cancer Res"},{"issue":"5","key":"4124_CR23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.immuni.2018.04.011","volume":"48","author":"K Pelka","year":"2018","unstructured":"Pelka K, Bertheloot D, Reimer E, Phulphagar K, Schmidt SV, Christ A, et al. The chaperone UNC93B1 regulates toll-like receptor stability independently of endosomal TLR transport. Immunity. 2018;48(5):911\u201322. https:\/\/doi.org\/10.1016\/j.immuni.2018.04.011.","journal-title":"Immunity"},{"key":"4124_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2041731414557112","volume":"5","author":"JK Kular","year":"2014","unstructured":"Kular JK, Basu S, Sharma RI. The extracellular matrix: structure, composition, age-related differences, tools for analysis and applications for tissue engineering. J Tissue Eng. 2014;5:1\u201317. https:\/\/doi.org\/10.1177\/2041731414557112.","journal-title":"J Tissue Eng"},{"issue":"8","key":"4124_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131458","volume":"6","author":"C Chen","year":"2021","unstructured":"Chen C, Li S, Xue J, Qi M, Liu X, Huang Y, et al. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. JCI Insight. 2021;6(8):e131458. https:\/\/doi.org\/10.1172\/jci.insight.131458.","journal-title":"JCI Insight"},{"issue":"9","key":"4124_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"issue":"2","key":"4124_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","volume":"5","author":"T Noguchi","year":"2017","unstructured":"Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017;5(2):106\u201317. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0391.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"4124_CR28","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a038026","volume":"10","author":"A Swierczak","year":"2020","unstructured":"Swierczak A, Pollard JW. Myeloid cells in metastasis. Cold Spring Harb Perspect Med. 2020;10(5):a038026. https:\/\/doi.org\/10.1101\/cshperspect.a038026.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"4124_CR29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ccell.2024.05.004","volume":"42","author":"CS McGinnis","year":"2024","unstructured":"McGinnis CS, Miao Z, Superville D, Yao W, Goga A, Reticker-Flynn NE, et al. The temporal progression of lung immune remodeling during breast cancer metastasis. Cancer Cell. 2024;42(6):1018\u201331. https:\/\/doi.org\/10.1016\/j.ccell.2024.05.004.","journal-title":"Cancer Cell"},{"issue":"4","key":"4124_CR30","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s10555-024-10189-4","volume":"43","author":"Y He","year":"2024","unstructured":"He Y, Zhu M, Lai X, Zhang H, Jiang W. The roles of PD-L1 in the various stages of tumor metastasis. Cancer Metastasis Rev. 2024;43(4):1475\u201388. https:\/\/doi.org\/10.1007\/s10555-024-10189-4.","journal-title":"Cancer Metastasis Rev"},{"key":"4124_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101405","volume":"20","author":"T Rupp","year":"2022","unstructured":"Rupp T, Genest L, Babin D, Legrand C, Hunault M, Froget G, et al. Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. Transl Oncol. 2022;20:101405. https:\/\/doi.org\/10.1016\/j.tranon.2022.101405.","journal-title":"Transl Oncol"},{"issue":"11","key":"4124_CR32","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1200\/JCO.22.02623","volume":"41","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for Sunitinib compared with Interferon Alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2023;41(11):1965\u201371. https:\/\/doi.org\/10.1200\/JCO.22.02623.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4124_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jjco\/hyz009","volume":"49","author":"T Ito","year":"2019","unstructured":"Ito T, Tori M, Hashigaki S, Kimura N, Sato K, Ohki E, et al. Efficacy and safety of Sunitinib in Japanese patients with progressive, advanced\/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study. Jpn J Clin Oncol. 2019;49(4):354\u201360. https:\/\/doi.org\/10.1093\/jjco\/hyz009.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"4124_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/tcrm.2007.3.2.341","volume":"3","author":"C Le Tourneau","year":"2007","unstructured":"Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag. 2007;3(2):341\u20138. https:\/\/doi.org\/10.2147\/tcrm.2007.3.2.341.","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"4124_CR35","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrd2380","volume":"6","author":"S Faivre","year":"2007","unstructured":"Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for Sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007;6(9):734\u201345. https:\/\/doi.org\/10.1038\/nrd2380.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"4124_CR36","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","volume":"26","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of Sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26(11):1810\u20136. https:\/\/doi.org\/10.1200\/JCO.2007.14.5375.","journal-title":"J Clin Oncol"},{"key":"4124_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-207","volume":"13","author":"D Zhang","year":"2014","unstructured":"Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q, et al. Twist1 expression induced by Sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer. 2014;13:207. https:\/\/doi.org\/10.1186\/1476-4598-13-207.","journal-title":"Mol Cancer"},{"issue":"4","key":"4124_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10585-021-10111-0","volume":"38","author":"E Wrenn","year":"2021","unstructured":"Wrenn E, Huang Y, Cheung K. Collective metastasis: coordinating the multicellular voyage. Clin Exp Metastasis. 2021;38(4):373\u201399. https:\/\/doi.org\/10.1007\/s10585-021-10111-0.","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"4124_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07406-4","volume":"9","author":"GV Echeverria","year":"2018","unstructured":"Echeverria GV, Powell E, Seth S, Ge Z, Carugo A, Bristow C, et al. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun. 2018;9(1):5079. https:\/\/doi.org\/10.1038\/s41467-018-07406-4.","journal-title":"Nat Commun"},{"key":"4124_CR40","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.2147\/OTT.S112242","volume":"9","author":"Z Hao","year":"2016","unstructured":"Hao Z, Sadek I. Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther. 2016;9:5495\u2013505. https:\/\/doi.org\/10.2147\/OTT.S112242.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"4124_CR41","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00280-008-0917-1","volume":"64","author":"JO Haznedar","year":"2009","unstructured":"Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, et al. Single- and multiple-dose disposition kinetics of Sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol. 2009;64(4):691\u2013706. https:\/\/doi.org\/10.1007\/s00280-008-0917-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4124_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5246\/jcps.2015.04.028","volume":"24","author":"J Li","year":"2015","unstructured":"Li J, Li J, Wang S, Yuan Y, Su Q, Lu W, et al. Simultaneous determination of sunitinib and its active metabolites N-desethylsunitinib (SU12662) in nude mice plasma by liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. J Chin Pharm Sci. 2015;24(4):217\u201324. https:\/\/doi.org\/10.5246\/jcps.2015.04.028.","journal-title":"J Chin Pharm Sci"},{"issue":"11","key":"4124_CR43","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.cell.2022.04.019","volume":"185","author":"NE Reticker-Flynn","year":"2022","unstructured":"Reticker-Flynn NE, Zhang W, Belk JA, Basto PA, Escalante NK, Pilarowski GOW, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022;185(11):1924\u201342. https:\/\/doi.org\/10.1016\/j.cell.2022.04.019.","journal-title":"Cell"},{"issue":"2","key":"4124_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-018-0321-2","volume":"25","author":"Y Xu","year":"2019","unstructured":"Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019;25(2):301\u201311. https:\/\/doi.org\/10.1038\/s41591-018-0321-2.","journal-title":"Nat Med"},{"key":"4124_CR45","unstructured":"Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, et al. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res. 2002;62(20):5727\u201335."},{"issue":"1","key":"4124_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30569-0","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, et al. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. 2022;13(1):3011. https:\/\/doi.org\/10.1038\/s41467-022-30569-0.","journal-title":"Nat Commun"},{"issue":"1","key":"4124_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01362-y","volume":"22","author":"M Quintela-Fandino","year":"2020","unstructured":"Quintela-Fandino M, Holgado E, Manso L, Morales S, Bermejo B, Colomer R, et al. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Res. 2020;22(1):124. https:\/\/doi.org\/10.1186\/s13058-020-01362-y.","journal-title":"Breast Cancer Res"},{"key":"4124_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.810747","volume":"13","author":"Y Fu","year":"2022","unstructured":"Fu Y, Liu J, Jiang Y. Partial response after toripalimab plus anlotinib for advanced metaplastic breast carcinoma: a case report. Front Endocrinol (Lausanne). 2022;13:810747. https:\/\/doi.org\/10.3389\/fendo.2022.810747.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"4124_CR49","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1158\/1535-7163.MCT-19-0495","volume":"19","author":"T Sun","year":"2020","unstructured":"Sun T, Zhang W, Li Y, Jin Z, Du Y, Tian J, et al. Combination immunotherapy with cytotoxic T-lymphocyte-associated antigen-4 and programmed death protein-1 inhibitors prevents postoperative breast tumor recurrence and metastasis. Mol Cancer Ther. 2020;19(3):802\u201311. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0495.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"4124_CR50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/psp4.12426","volume":"8","author":"G Helmlinger","year":"2019","unstructured":"Helmlinger G, Sokolov V, Peskov K, Hallow KM, Kosinsky Y, Voronova V, et al. Quantitative systems pharmacology: an exemplar model-building workflow with applications in cardiovascular, metabolic, and oncology drug development. CPT Pharmacomet Syst Pharmacol. 2019;8(6):380\u201395. https:\/\/doi.org\/10.1002\/psp4.12426.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"4124_CR51","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/cpt.1786","volume":"107","author":"G Lazarou","year":"2020","unstructured":"Lazarou G, Chelliah V, Small BG, Walker M, van der Graaf PH, Kierzek AM. Integration of omics data sources to inform mechanistic modeling of immune-oncology therapies: A tutorial for clinical pharmacologists. Clin Pharmacol Ther. 2020;107(4):858\u201370. https:\/\/doi.org\/10.1002\/cpt.1786.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04124-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:44:42Z","timestamp":1783629882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04124-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4124"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04124-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author reports no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}